Gene expression profiling in multiple myeloma: Redefining the paradigm of risk-adapted treatment Review
| Authors: | Cerchione, C.; Usmani, S. Z.; Stewart, A. K.; Kaiser, M.; Rasche, L.; Kortüm, M.; Mateos, M. V.; Spencer, A.; Sonneveld, P.; Anderson, K. C. |
| Review Title: | Gene expression profiling in multiple myeloma: Redefining the paradigm of risk-adapted treatment |
| Abstract: | Multiple myeloma is a blood cancer characterized by clonal proliferation of plasma cells in the bone marrow. In recent years, several new drugs have been added to the therapeutic landscape of multiple myeloma, which have contributed to increased survival rates. However, while the use of therapeutics has evolved, there is still a group of high-risk patients who do not benefit from current treatment strategies. Risk stratification and risk-adapted treatment are crucial to identify the group of patients with urgent need for novel therapies. Gene expression profiling has been introduced as a tool for risk stratification in multiple myeloma based on the genetic make-up of myeloma cells. In this review we discuss the challenge of defining the high-risk multiple myeloma patient. We focus on the standardized analysis of myeloma cancer cells by gene expression profiling and describe how gene expression profiling provides additional insights for optimal risk-adapted treatment of patients suffering from multiple myeloma. Copyright © 2022 Cerchione, Usmani, Stewart, Kaiser, Rasche, Kortüm, Mateos, Spencer, Sonneveld and Anderson. |
| Keywords: | adult; cancer chemotherapy; cancer survival; protein expression; treatment response; survival rate; major clinical study; overall survival; lenalidomide; thalidomide; review; cancer patient; gadolinium; flow cytometry; cell proliferation; biological marker; progression free survival; multiple myeloma; gene expression; gene expression profiling; bone marrow; tumor volume; cytogenetics; creatinine; cyclophosphamide; dexamethasone; melphalan; autologous stem cell transplantation; transcriptomics; high risk patient; risk assessment; plasma cell; disease severity; fluorescence in situ hybridization; genomic instability; risk stratification; interleukin 6; clinical decision making; lactate dehydrogenase; karyotyping; lactate blood level; principal component analysis; clinical outcome; myeloma cell; decision tree; pomalidomide; cancer prognosis; novel agents; risk-adapted treatment; human; male; female; daratumumab; gene expression profiling (gep); sky92 |
| Journal Title: | Frontiers in Oncology |
| Volume: | 12 |
| ISSN: | 2234-943X |
| Publisher: | Frontiers Media S.A. |
| Date Published: | 2022-02-08 |
| Start Page: | 820768 |
| Language: | English |
| DOI: | 10.3389/fonc.2022.820768 |
| PROVIDER: | scopus |
| PMCID: | PMC8861274 |
| PUBMED: | 35211412 |
| DOI/URL: | |
| Notes: | Review -- Export Date: 1 April 2022 -- Source: Scopus |
